Novo Nordisk Seeks to Block Compounded Victoza
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.
New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.
